Amyotrophic lateral sclerosis (ALS) affects more than 5,600 new Americans every year.

 

Often referred to as Lou Gehrig's disease, ALS is the most common form of motor neuron disease, affecting about 30,000 people in the United States. Symptoms of ALS in the early stages include muscle weakness and progresses to full motor paralysis and sever muscular atropy.

Miller Laboratory is dedicated to understanding ALS and developing new, effective and safe treatments. Located at Washington University School of Medicine in St. Louis, Miller Laboratory is headed by Dr. Timothy Miller, an assistant professor in neurology and a specialist in neurophysiology. Currently, Miller Lab is working on new treatments based on micro-RNA research.

More information >>

 

Packard Investigator Timothy Miller highlights new potential therapeutic target for ALS.

Read more >>

 

New ALS treatment enters Phase II Clinical Trial.

Read more >>